Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

Clodagh Towns,Madeleine Richer,Simona Jasaityte,Eleanor J. Stafford,Julie Joubert,Tarek Antar,Alejandro Martinez-Carrasco,Mary B. Makarious,Bradford Casey,Dan Vitale,Kristin Levine,Hampton Leonard,Caroline B. Pantazis,Laurel A. Screven,Dena G. Hernandez,Claire E. Wegel,Justin Solle,Mike A. Nalls,Cornelis Blauwendraat,Andrew B. Singleton,Manuela M. X. Tan,Hirotaka Iwaki,Huw R. Morris,Emilia M. Gatto,Marcelo Kauffman,Samson Khachatryan,Zaruhi Tavadyan,Claire E. Shepherd,Julie Hunter,Kishore Kumar,Melina Ellis,Miguel E. Rentería,Sulev Koks,Alexander Zimprich,Artur F. Schumacher-Schuh,Carlos Rieder,Paula Saffie Awad,Vitor Tumas,Sarah Camargos,Edward A. Fon,Oury Monchi,Ted Fon,Benjamin Pizarro Galleguillos,Marcelo Miranda,Maria Leonor Bustamante,Patricio Olguin,Pedro Chana,Beisha Tang,Huifang Shang,Jifeng Guo,Piu Chan,Wei Luo,Gonzalo Arboleda,Jorge Orozco,Marlene Jimenez del Rio,Alvaro Hernandez,Mohamed Salama,Walaa A. Kamel,Yared Z. Zewde,Alexis Brice,Jean-Christophe Corvol,Ana Westenberger,Anastasia Illarionova,Brit Mollenhauer,Christine Klein,Eva-Juliane Vollstedt,Franziska Hopfner,Günter Höglinger,Harutyun Madoev,Joanne Trinh,Johanna Junker,Katja Lohmann,Lara M. Lange,Manu Sharma,Sergiu Groppa,Thomas Gasser,Zih-Hua Fang,Albert Akpalu,Georgia Xiromerisiou,Georgios Hadjigorgiou,Ioannis Dagklis,Ioannis Tarnanas,Leonidas Stefanis,Maria Stamelou,Efthymios Dadiotis,Alex Medina,Germaine Hiu-Fai Chan,Nancy Ip,Nelson Yuk-Fai Cheung,Phillip Chan,Xiaopu Zhou,Asha Kishore,Divya KP,Pramod Pal,Prashanth Lingappa Kukkle,Roopa Rajan,Rupam Borgohain,Mehri Salari,Andrea Quattrone,Enza Maria Valente,Lucilla Parnetti,Micol Avenali,Tommaso Schirinzi,Manabu Funayama,Nobutaka Hattori,Tomotaka Shiraishi,Altynay Karimova,Gulnaz Kaishibayeva,Cholpon Shambetova,Rejko Krüger,Ai Huey Tan,Azlina Ahmad-Annuar,Mohamed Ibrahim Norlinah,Nor Azian Abdul Murad,Shahrul Azmin,Shen-Yang Lim,Wael Mohamed,Yi Wen Tay,Daniel Martinez-Ramirez,Mayela Rodriguez-Violante,Paula Reyes-Pérez,Bayasgalan Tserensodnom,Rajeev Ojha,Tim J. Anderson,Toni L. Pitcher,Arinola Sanyaolu,Njideka Okubadejo,Oluwadamilola Ojo,Jan O. Aasly,Lasse Pihlstrøm,Manuela Tan,Shoaib Ur-Rehman,Mario Cornejo-Olivas,Maria Leila Doquenia,Raymond Rosales,Angel Vinuela,Elena Iakovenko,Bashayer Al Mubarak,Muhammad Umair,Eng-King Tan,Jia Nee Foo,Ferzana Amod,Jonathan Carr,Soraya Bardien,Beomseok Jeon,Yun Joong Kim,Esther Cubo,Ignacio Alvarez,Janet Hoenicka,Katrin Beyer,Maria Teresa Periñan,Pau Pastor,Sarah El-Sadig,Christiane Zweier,Paul Krack,Chin-Hsien Lin,Hsiu-Chuan Wu,Pin-Jui Kung,Ruey-Meei Wu,Yihru Wu,Rim Amouri,Samia Ben Sassi,A. Nazlı Başak,Gencer Genc,Özgür Öztop Çakmak,Sibel Ertan,Alastair Noyce,Anette Schrag,Anthony Schapira,Camille Carroll,Claire Bale,Donald Grosset,Henry Houlden,John Hardy,Kin Ying Mok,Mie Rizig,Nicholas Wood,Nigel Williams,Olaitan Okunoye,Patrick Alfryn Lewis,Rauan Kaiyrzhanov,Rimona Weil,Seth Love,Simon Stott,Simona Jasaitye,Sumit Dey,Vida Obese,Alberto Espay,Alyssa O’Grady,Andrew K. Sobering,Bernadette Siddiqi,Brian Fiske,Cabell Jonas,Carlos Cruchaga,Charisse Comart,Claire Wegel,Deborah Hall,Dena Hernandez,Ejaz Shiamim,Ekemini Riley,Faraz Faghri,Geidy E. Serrano,Honglei Chen,Ignacio F. Mata,Ignacio Juan Keller Sarmiento,Jared Williamson,Jonggeol Jeff Kim,Joseph Jankovic,Joshua Shulman,Justin C. Solle,Kaileigh Murphy,Karen Nuytemans,Karl Kieburtz,Katerina Markopoulou,Kenneth Marek,Kristin S. Levine,Lana M. Chahine,Laura Ibanez,Laurel Screven,Lauren Ruffrage,Lisa Shulman,Luca Marsili,Maggie Kuhl,Marissa Dean,Mathew Koretsky,Megan J. Puckelwartz,Miguel Inca-Martinez,Naomi Louie,Niccolò Emanuele Mencacci,Roger Albin,Roy Alcalay,Ruth Walker,Sara Bandres-Ciga,Sohini Chowdhury,Sonya Dumanis,Steven Lubbe,Tao Xie,Tatiana Foroud,Thomas Beach,Todd Sherer,Yeajin Song,Duan Nguyen,Toan Nguyen,Masharip Atadzhanov,
DOI: https://doi.org/10.1038/s41531-023-00533-w
2023-09-12
Abstract:Abstract The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia.
neurosciences
What problem does this paper attempt to address?